Skip to content

A randomized controlled trial for honeysuckle decoction in the treatment of patients with novel coronavirus (COVID-19) infection

A randomized controlled trial for honeysuckle decoction in the treatment of patients with novel coronavirus (COVID-19) infection

Status
Unknown
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000029822
Enrollment
Unknown
Registered
2020-02-14
Start date
2020-02-07
Completion date
Unknown
Last updated
2020-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel Coronavirus Pneumonia (COVID-19)

Interventions

Experimental group:honeysuckle decoction
Control group:placebo

Sponsors

Nanjing Second Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 100 Years

Inclusion criteria

Inclusion criteria: 1. Age is not limited; 2. Clinical diagnosis is in accordance with the "Notice on issuing a new type of coronavirus pneumonia diagnosis and treatment program (Fifth edition)" on the diagnosis of a new type of coronavirus infection; 3. potable decoction; 4. no honeysuckle allergy; 5. child-bearing age female subjects pregnancy test negative person; 6. child-bearing age female subjects pregnancy test positive person needs targeted communication, the patient's consent can be included; 7. pregnancy or breast-feeding subjects need targeted communication, the patient's consent can be included in the voluntary informed consent signed by the person under the age of 16.

Exclusion criteria

Exclusion criteria: (1) Those who cannot take Chinese traditional medicine decoction; (2) mentally ill subjects who are not easy to control; (3) those who are pregnant or breast-feeding; (4) those who use other Chinese medicines; (5) those who are not considered suitable to participate in this trial by researchers.

Design outcomes

Primary

MeasureTime frame
rate of cure;

Secondary

MeasureTime frame
time to temperature normal;breath symptoms and measure;hospitalization days;

Countries

China

Contacts

Public ContactYongxiang Yi

Nanjing Second Hospital

ian0126@126.com+86 13338628626

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026